Brickell Biotech Inc. (NASDAQ: BBI) stock fell -3.82% on Friday to $4.03 against a previous-day closing price of $4.19. With 1.11 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.25 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $4.2900 whereas the lowest price it dropped to was $3.6200. The 52-week range on BBI shows that it touched its highest point at $37.35 and its lowest point at $2.88 during that stretch. It currently has a 1-year price target of $48.75. Beta for the stock currently stands at 0.03.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of BBI was up-trending over the past week, with a rise of 33.89%, but this was up by 12.89% over a month. Three-month performance dropped to -65.56% while six-month performance fell -62.69%. The stock lost -86.22% in the past year, while it has lost -60.88% so far this year. A look at the trailing 12-month EPS for BBI yields -20.51 with Next year EPS estimates of -8.47. For the next quarter, that number is -1.44. This implies an EPS growth rate of 42.40% for this year and -5.00% for next year.
Float and Shares Shorts:
At present, 2.65 million BBI shares are outstanding with a float of 2.62 million shares on hand for trading. On Jul 14, 2022, short shares totaled 0.18 million, which was 6.83% higher than short shares on Jun 14, 2022. In addition to Mr. Reginald L. Hardy M.B.A., R.Ph. as the firm’s Co-Founder & Chairman, Attorney Robert Busard Brown serves as its CEO & Director.
Through their ownership of 15.95% of BBI’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 0.00% of BBI, in contrast to — held by mutual funds. Shares owned by individuals account for –. With a 0.00% stake in BBI, the iShares Core S&P Total US Stock M is the largest stakeholder. A total of 21 shares are owned by the mutual fund manager.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for BBI since 3 analysts follow the stock currently. There are 2 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 1 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With BBI analysts setting a high price target of $45.00 and a low target of $11.25, the average target price over the next 12 months is $22.75. Based on these targets, BBI could surge 1016.63% to reach the target high and rise by 179.16% to reach the target low. Reaching the average price target will result in a growth of 464.52% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. BBI will report FY 2022 earnings on 03/22/2023. Analysts have provided yearly estimates in a range of -$7.65 being high and -$9.11 being low. For BBI, this leads to a yearly average estimate of -$8.44. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Brickell Biotech Inc. surprised analysts by -$1.01 when it reported -$3.60 EPS against a consensus estimate of -$2.59. The surprise factor in the prior quarter was $1.13. Based on analyst estimates, the high estimate for the next quarter is -$1.35 and the low estimate is -$1.61. The average estimate for the next quarter is thus -$1.44.
Summary of Insider Activity:
Insiders traded BBI stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has remained unchanged to 0 while that of sell transactions has risen to 1 over the past year. The total number of shares bought during that period was 0 while 15,180 shares were sold.